Furthermore, according to recent preclinical evidence, the timing of BACE1 inhibitors administration in clinical testing should be adapted for early stages of AD when BACE1 inhibition is expected to have the highest impact in preventing amyloid plaque deposition [16,17]. This evidence concerns the gene BACE1 and Alzheimer disease.